JP Morgan Reinstates Neutral on Esperion Therapeutics
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Jessica Fye has reinstated coverage on Esperion Therapeutics (NASDAQ:ESPR) with a Neutral rating.

November 20, 2023 | 1:26 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Esperion Therapeutics has been reinstated with a Neutral rating by JP Morgan analyst Jessica Fye.
The reinstatement of coverage by a major bank like JP Morgan with a Neutral rating suggests a balanced view on the stock's prospects. It neither predicts a strong upside nor a significant downside, indicating a stable outlook for the stock in the short term. This could lead to a neutral market reaction.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100